

**MYLAN N.V.**  
Reported by  
**ABBOTT INVESTMENTS LUXEMBOURG S.A R.L.**

**FORM 4**  
(Statement of Changes in Beneficial Ownership)

Filed 03/24/17 for the Period Ending 03/23/17

Telephone	44 0 1707 853 000
CIK	0001623613
Symbol	MYL
SIC Code	2834 - Pharmaceutical Preparations
Industry	Pharmaceuticals
Sector	Healthcare
Fiscal Year	12/31

# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL  
OMB Number: 3235-0287  
Estimated average burden  
hours per response... 0.5

[ X ] Check this box if no longer  
subject to Section 16. Form 4 or  
Form 5 obligations may  
continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or  
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
<b>ABBOTT LABORATORIES</b>			<b>Mylan N.V. [ MYL ]</b>			<input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)					
<b>100 ABBOTT PARK ROAD, AP6A-2, D-032L</b>			<b>3/23/2017</b>					
(Street)			4. If Amendment, Date Original Filed (MM/DD/YYYY)			6. Individual or Joint/Group Filing (Check Applicable Line)		
<b>ABBOTT PARK, IL 60064-6092</b>						<input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
(City)			(State)			(Zip)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares, nominal value Euro 0.01 per share	3/23/2017		S		44000000	D	\$41.60	25750000	I	By Subsidiaries

**Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

#### Explanation of Responses:

#### Remarks:

The Ordinary Shares of Mylan N.V. ("Mylan") described in this report are held directly by Abbott Products and Abbott Investments Luxembourg S.a.r.l (collectively, the "Subsidiaries"). Each of the Subsidiaries is an indirect, wholly-owned subsidiary of Abbott Laboratories ("Abbott"). In Abbott's capacity as the ultimate corporate parent of the Subsidiaries, Abbott may be deemed to indirectly beneficially own such Ordinary Shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Securities and Exchange Commission thereunder. The reported sale price does not include discounts and commissions. As a result of the reported sale transaction, Abbott and the Subsidiaries are no longer subject to the reporting requirements of Section 16 with respect to their beneficial ownership of Mylan Ordinary Shares.

#### Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
<b>ABBOTT LABORATORIES</b> <b>100 ABBOTT PARK ROAD</b> <b>AP6A-2, D-032L</b> <b>ABBOTT PARK, IL 60064-6092</b>		X		
<b>Abbott Products</b> <b>100 ABBOTT PARK ROAD</b> <b>AP6A-2, D-032L</b> <b>ABBOTT PARK, IL 60064-6092</b>		X		
<b>Abbott Investments Luxembourg S.A R.L.</b> <b>100 ABBOTT PARK ROAD</b> <b>AP6A-2, D-032L</b> <b>ABBOTT PARK, IL 60064-6092</b>		X		

---

**Signatures**

/s/ Hubert L. Allen, Attorney-in-Fact

3/23/2017

\*\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.